Clinical Trials Logo

Clinical Trial Summary

A quarter of a million women will develop breast cancer (BC) in this year alone. Many of these women will have side effects as a result of their breast cancer treatment. Radiation Fibrosis Syndrome (RFS) is a common complication from breast cancer treatment that progressively changes tissue and can cause decreased function, pain, and range of motion. The PhysioTouch is a hand held device that can be used to treat RFS and may improve the treatment of fibrotic tissue. This pilot randomized controlled trial aims to determine the efficacy of using the PhysioTouch in addition to current standard of care for treatment of BC-related RFS.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03496909
Study type Interventional
Source University of Michigan
Contact Katie Rogers, MSOTR-CLT
Phone 734-232-1217
Email kathroge@med.umich.edu
Status Not yet recruiting
Phase N/A
Start date December 2018
Completion date April 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00041223 - IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer Phase 2
Completed NCT00020631 - Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer N/A
Withdrawn NCT00880386 - Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer N/A
Completed NCT00589121 - Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg Phase 2
Terminated NCT00077064 - Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy Phase 2
Completed NCT03462524 - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology N/A
Active, not recruiting NCT00077090 - Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer Phase 2